Research on the Safety of β-Blockers During Pregnancy
Study Overview
A research team in California conducted a study to evaluate the safety of β-blockers during pregnancy. Their findings revealed no significant association between the use of β-blockers and the risk of congenital cardiac anomalies in the fetus.
Common Use of β-Blockers
β-blockers are frequently prescribed for heart conditions in pregnant women. It is known that these medications can cross the placenta, and exposure has been linked to potential issues such as bradycardia and hypoglycemia in newborns. Additionally, previous studies have raised concerns about the possibility of β-blockers causing fetal congenital heart malformations.
Publication of Findings
The authors published their research in the Journal of the American Medical Association Internal Medicine. The study followed 379,238 pregnancies from 2003 to 2014, with 4,847 pregnant women exposed to β-blockers.
Characteristics of Participants
Pregnant women who used β-blockers were generally older, had a higher body mass index (BMI), and were more likely to have been diagnosed with various conditions, including hypertension, preeclampsia, eclampsia, hyperlipidemia, diabetes, heart failure, and arrhythmia.
Analysis of Results
In an unadjusted analysis, the use of β-blockers appeared to significantly increase the risk of fetal congenital anomalies. However, after adjusting for factors such as maternal age, BMI, and comorbidities, the significant association was no longer present.
Conclusion
The study concludes that the use of β-blockers during pregnancy is considered safe and does not elevate the risk of congenital heart disease in the fetus.
Author Information
Written by: Dr. Fanni R. Eros